secwatch.observer — SEC 8-K summary
======================================

Issuer:     Onconetix, Inc. (ONCO)
CIK:        0001782107
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001213900-25-018867
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 5.08, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Onconetix appoints James Sapirstein as Executive Chairman; former Interim CEO resigns
--------------------------------------------------------------------------------

- Dr. Ralph Schiess resigned as Interim CEO and CSO effective Feb 24, 2025; also to leave Proteomedix AG CEO role on May 31, 2025.
- James Sapirstein, existing Board member, appointed Executive Chairman; he is also CEO of Entero Therapeutics (Nasdaq: ENTO).
- Sapirstein compensated $400/hour for up to 20 hours/week; payment contingent on company securing sufficient capital.
- Board expanded from five to six; Andrew Oakley appointed as Class II director; former CFO at Autolus, Sosei, Vectura, Actelion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/0001213900-25-018867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782107/000121390025018867/ea0232572-8k_onconetix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-018867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer